The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Food effect substudy of a phase 3 randomized double-blind trial of maintenance with niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor versus placebo in patients with platinum-sensitive ovarian cancer.
Kathleen N. Moore
No relevant relationships to disclose
Zhi-Yi Zhang
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Shefali Agarwal
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Manish R. Patel
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
Robert E. Martell
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Vikram Kansra
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro